An appeal for generic biologic legislation
The following appeal for generic biologic legislation was sent in from Insmed via youtube.
I’ve posted previously on the challenges of developing a framework for generic biologic approvals and questioned how much we can really expect to save. In the editorial for the upcoming issue of the Journal of Commercial Biotechnology, I argue that the United States is unlikely to lead in generic biologic regulation.
Got any ideas to overcome the challenges? I’d love to post them here or at the Journal of Commercial Biotechnology.